Covinnovations™ Receives Positive Comments from National Institute of Health

Covinnovations™ recently received some positive and encouraging comments on its funding application to the National Institue of Health (NIH), with emphasis on the validity of the science behind COVID treatment COVI-001, which has demonstrated the potential to directly combat and halt COVID-19 after people have become infected with the disease, particularly those with intense reactions which have been hospitalized and are receiving oxygen.  

Additionally, the NIH lauded the team of professional who are behind the work at Covinnovations™, including Dr. Aury Nagy, a neurosurgeon with “extensive experience,” and the company’s lead scientist Dr. Amy Stone, whose “relevant research experience in working with RNA viruses” was noted. 

Other comments included: 

• The combination of two FDA-approved drugs reduces the safety and regulatory risks associated with developing completely novel compounds; and also increases the commercialization of the product. 

• The subcontracting organizations on the proposal are world class and have a long track record of executing on development; they have good facilities to carry out the proposed work. 

• A strong experienced team in immunology, chemistry and clinical care.